You are here

Furopyrroles as Novel anti-Ebola Agents

Award Information
Agency: Department of Health and Human Services
Branch: Centers for Disease Control and Prevention
Contract: 1R43CK000495-01
Agency Tracking Number: R43CK000495
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCZVBED
Solicitation Number: PA15-269
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-30
Award End Date (Contract End Date): 2018-09-29
Small Business Information
Chicago, IL 60612-3515
United States
DUNS: 079936940
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (630) 915-7094
Business Contact
Phone: (630) 915-4575
Research Institution

DESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenesis in humans Africa has recently suffered a lethal EBOV epidemic which has spilled over to other continents including the United States underscoring the urgency of antiviral drug discovery and development This application defines a plan to develop potent small molecule inhibitors which block entry of EBOV We have identified compounds that inhibit entry of infectious EBOV MARV IC values M These hit compounds exhibit selectivity for EBOV MARV entry The overall objective of this Phase I application is to develop these inhibitors as potential anti EBOV therapeutics This application will focus on the following three specific aims Synthesize structurally diverse analogs of the anti Ebola CBS hit series based on structure activity relationships SARs to improve potency and selectivity Validate the lead inhibitor candidates in the infectious assay and investigate the mechanism of action MOA of the EBOV inhibitors Select EBOV inhibitors with in vitro ADME properties suitable for i v and oral dosing

PUBLIC HEALTH RELEVANCE This project is to discover and develop small molecule entry inhibitors for Ebola viral infection The proposed research will help to develop potential antivira therapeutics

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government